Biopure restructures management, cuts staff by 25
This article was originally published in Clinica
Executive Summary
Cambridge, Massachusetts-based blood substitute firm Biopure has announced a company restructure and initiated a corporate strategic realignment. Zafiris Zafirelis, previously CEO of MedQuest, has been appointed president and CEO, and a member of the board of directors. He replaces Thomas Moore, who left in February (see Clinica No 1097, p 15).